CIDRAP newsletters options
Other states report more cases, including Minnesota, with two, one of which involves a child whose infection suggests community spread.
Nearly 1,000 final progress reports (less than 1% of awards made from 2014 through 2024) were delinquent.
Vaccines averted the highest rate of deaths during the Delta period, with 68% of deaths averted.
The US has been hit hardest, with more than 10,000 cases and 5 deaths, 4 of them in children younger than 1 year.
Among 45 cases, 16 people have required hospitalization.
The company's "next-generation" COVID-19 vaccine, mNexspike, was approved for adults 65 and older and younger people at risk of severe disease.
A retrospective analysis of hospitalized VA patients finds that prior flu or RSV infection more than doubled the odds of subsequent Streptococcus pneumoniae infection.
The results of the non–peer-reviewed research highlight the risk of contracting H5N1 avian flu from unpasteurized dairy products or occupational exposure in dairies.
Emphasizing shared clinical decision-making with providers, the CDC now says healthy children ages 6 to 17 "may" receive COVID vaccination if a parent or guardian wants it.
Some of the latest cases are tied to a large outbreak centered in West Texas, while others are linked to instances of community transmission or travel to other states or countries.
The woman had amebic meningoencephalitis, a rare, often fatal brain infection caused by the ameba Naegleria fowleri.
Cholera cases in Africa have risen sharply this year, with illnesses on track to pass totals recorded in 2023 and 2024.
A Trump administration report outlining the potential factors related to the rise in chronic diseases in US children cites several studies that don't exist.
The CDC has reported large Salmonella outbreaks tied to poultry in each of the past few years, with more than 1,000 cases in both 2022 and 2023.
Of 142 deer farms and hunting ranches in Wisconsin, a third have been hit with CWD since 2001.
The WHO is recommending use of a maternal RSV vaccine and the monoclonal antibody nirsevimab to protect infants against the virus.
Buoyed by promising clinical findings, Moderna says it will explore alternatives for late-stage development of the H5 vaccine.
An interim analysis of trial data finds that tebipenem HBr met its primary efficacy end point in patients with complicated urinary tract infections, including pyelonephritis.
The higher death rate was likely driven by strained healthcare systems amid the pandemic and more patients susceptible to Candida species because of severe COVID-19, the researchers say.
Neutralizing antibodies tested 90 days after infection were greater in participants who had been vaccinated before their variant infections than in those who had been vaccine-naive.
